Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START: Dapagliflozin vs Metformin for Renal Decline in T2D
NCT05345327Phase 3Recruiting
- Sponsor
- The George Institute for Global Health
- Start
- Jan 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by The George Institute for Global Health. Started Jan 2023; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05345327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05345327.